Hepcidin and Glucose Metabolism

Launched by SWISS FEDERAL INSTITUTE OF TECHNOLOGY · Jul 1, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how iron supplements during pregnancy might affect a hormone called hepcidin, which plays a role in iron metabolism, and whether this change impacts blood sugar control. The researchers are particularly interested in women who are between 24 to 28 weeks pregnant and may be dealing with conditions like iron deficiency anemia or gestational diabetes. These conditions are common during pregnancy and can lead to complications for both the mother and the baby.

To participate in the study, women need to have a body mass index (BMI) under 27.5, a hemoglobin level above 8.0 g/dl, and be carrying a single baby. Participants will either avoid iron supplements for 14 days or take a specific multivitamin with iron during that time. Throughout the study, participants will be monitored to see how their body responds to the iron supplementation. This research is important because it aims to help improve the health of pregnant women and their babies by understanding how iron and blood sugar levels interact.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • week of pregnancy 24-28
• • pre-pregnancy BMI \<27.5kg/m2
• • singleton pregnancy
• • Hb \> 8.0 g/dl
• Willing to either:
• • not take any iron supplements for 14 days (however, participants will receive a similar amount of total iron during the 4 study days that they would normally receive over 14 days) OR
• • to take the multivitamin "Burgerstein Schwangerschaft and Stillzeit" supplements over the 14 days (contains 30 mg iron)
• Exclusion Criteria:
• • iron infusion within the past 6 months
• • severely anemic Hb\<8.0g/dl
• • acute or chronic disease
• • long-term medication
• • medical problems known to affect iron homeostasis
• • smoking